← Back

Ottobock SE & Co. KGaA

Ottobock SE & Co. KGaA develops, produces, and distributes medical technology products and components for people with disabilities. Its offerings span prosthetics, orthotics, human mobility, and industrial exoskeletons, serving Europe, the Middle East, Africa, North and South America, and Asia Pacific. The company also provides fitting solutions, rehabilitation solutions, wheelchairs, and related services. Formerly Otto Bock HealthCare GmbH, it changed its name to Ottobock SE & Co. KGaA in April 2018. Founded in 1919, it is based in Duderstadt, Germany, and operates as a subsidiary of Näder Upside 2 Vermögensverwaltungs GmbH.

Price · split & dividend adjusted
News & notes moving OBCK.XETRA
Aging Population▲

Ottobock to acquire Fesia Technology to expand neuro-orthotics portfolio

Ottobock has agreed to acquire Spanish medical device company Fesia Technology in a strategic move to expand its neuro-orthotics portfolio with functional electrical stimulation products. The deal, expected to close within six months, will bring Fesia's wearable FES orthoses for treating neuromuscular issues from conditions like stroke, multiple sclerosis, and cerebral palsy under Ottobock's umbrella. Financial terms were not disclosed. Fesia's devices, including Fesia Walk for foot drop and Fesia Grasp for hand movements, are controlled via a smartphone app for customized stimulation. Ottobock CEO Oliver Jakobi said the acquisition provides an innovative FES technology platform to strengthen the company's role in the growing neurological disease market.
OBCK.XETRA ▲
Aging Population
About megatrends
Aging Population › Mobility Aids & Assistive Technology Competition
OBCK.XETRA · Technology · Positive Acquires Fesia's innovative FES technology platform, expanding neuro-orthotics portfolio.
Fesia Technology · Capital · Positive Acquired by Ottobock, providing exit and integration into larger portfolio.
Read original ↗
Medical Device Network·90dRead more →
OBCK.XETRA

Ottobock Appoints Dr. Katarzyna Mazur-Hofsaess to Management Board

Ottobock SE & Co. KGaA has appointed Dr. Katarzyna Mazur-Hofsaess to its Management Board effective 22 June 2026. She succeeds Stefan Heidenreich, whose regular five-year term has ended. Dr. Mazur-Hofsaess brings extensive international experience in medical technology and healthcare, having served on the Management Board of Fresenius Medical Care and as CEO of its Care Enablement segment from 2018 to 2025, and previously leading the EMEA region at Zimmer Biomet. A physician by training, she earned her doctorate at the Medical University of Gdansk and also completed management studies at the Warsaw School of Economics and the University of Minnesota. Ottobock thanked Stefan Heidenreich for his role as Deputy Chairman in shaping the company's strategic development into a listed entity.
OBCK.XETRA
OBCK.XETRA · Capital · Neutral Appointment of a new management board member; strategic development into a listed entity mentioned, but no clear positive or negative impact.
Read original ↗
NewsMediaWire·103dRead more →
© 2026 MarketIVAsset